Protective effect of porcine placenta in a menopausal ovariectomized mouse

Na-Ra Han, Chan-Lee Park, Na-Rae Kim, Hee-Yun Kim, Myoung-Schook Yoou, Sun-Young Nam, Phil-Dong Moon, Hyun-Ja Jeong¹ and Hyung-Min Kim

Department of Pharmacology, College of Korean Medicine, Kyung Hee University, 26, Kyungheedaero-ro, Dongdaemun-gu, Seoul 130–701, Republic of Korea and ¹Department of Food Technology, Inflammatory Disease Research Center, Hoseo University, 20, Hoseo-ro 79beon-gil, Baebang-eup, Asan, Chungcheongnam-do 336–795, Republic of Korea

Correspondence should be addressed to H-M Kim; Email: hmkim@khu.ac.kr or to H-J Jeong; Email: hjjeong@hoseo.edu

The journal and the authors apologise for an error in the section on Preparation of PPE, Arg and 17 β -estradiol in this article published in the September 2015 issue (vol 150 pp 173–181). Lyophilized powder of porcine placenta should read as Enzyme hydrolyzed powder of porcine placenta. The corrected section is published in full below:

Preparation of PPE, Arg, and 17 β -estradiol

Enzyme hydrolyzed powder of porcine placenta was obtained from Cellamedic Korea Co. (Seoul, Republic of Korea), dissolved in distilled water (DW), filtered with 0.22 μ m syringe filter, and prepared at doses of 0.1, 1, and 10 μ g/ml according to a previous report (Han *et al.* 2013). Arg (Sigma Chemical Co.) was also dissolved in DW, filtered with 0.22 μ m syringe filter, prepared at a dose of 10 μ g/ml according to a previous report (Han *et al.* 2013). 17 β -estradiol (E₂, Sigma Chemical Co.) was dissolved in dimethyl sulfoxide, filtered with 0.22 μ m syringe filter, prepared at a dose of 100 nM according to a previous report (Choi *et al.* 2011).